News & Events

events
Conference
April 2, 2026
InSysBio to take part in ChinaBio Partnering Forum 2026
InSysBio announces its participation in ChinaBio Partnering Forum 2026 which is to be held from April 28–29, 2026 in Shanghai, China. InSysBio team is going to present its QSP modeling services & software to optimize drug development at Booth #B302 and a poster at the Antibody & ADC Summit
LEARN MORE
events
Conference
March 12, 2026
InSysBio to participate in QSPC 2026
InSysBio announces its participation in QSPC 2026 which is to be held from April 8-10, 2026 in Leiden, the Netherlands. InSysBio team is going to present its QSP modeling services & software to optimize drug development at Booth #3 and posters. Moreover, InSysBio will hold a workshop on Heta.
LEARN MORE
events
Conference
Software
February 25, 2026
InSysBio to hold a workshop on Heta at QSPC 2026

Engineering-Style QSP Modeling with Heta

InSysBio announces the upcoming workshop on Heta at QSPC 2026. The worksop will be held at Golden Tulip & Tulip Inn Leiden Centre, Leiden, the Netherlands on April 7, 2026, 1 PM – 5 PM.
LEARN MORE
events
Conference
February 18, 2026
InSysBio to take part in AGAH Conference 2026
InSysBio announces its participation in AGAH Conference 2026 (The Association for Applied Human Pharmacology) which is to be held from February 25-26, 2026 in Frankfurt, Germany. Oleg Demin, Chief Scientific Advisor and co-founder of InSysBio, is going to present a poster selected for the Poster Pitch at Session 4 Poster Slam
LEARN MORE
NEWS
Press-Release
January 28, 2026
InSysBio to announce a new collaborative project with BeOne Medicines

The project aims at Quantitative Systems Pharmacology modeling of a T-cell engager to identify first-in-human dose and predict optimal step-up dosing regimen

InSysBio, one of the world's pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the extension of collaboration with BeOne Medicines, a global oncology company.
LEARN MORE
NEWS
Press-Release
October 29, 2025
InSysBio to announce its collaboration with BeOne Medicines

The project aims at mechanistic PK/RO modeling to predict optimal dose and regimen of BGB-B2033, GPC3 x 4-1BB bispecific antibody

InSysBio, one of the world's pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with BeOne Medicines, a global oncology company.
LEARN MORE
December 2058
MoTuWeThFrSaSu
      
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
     
Upcoming Events
07.04
InSysBio to hold a workshop on Heta at QSPC 2026
08.04
InSysBio to participate in QSPC 2026
28.04
InSysBio to take part in ChinaBio Partnering Forum 2026
Tags